American Journal of Clinical Dermatology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review
AbstractGenodermatoses are genetically inherited dermatologic conditions. The management of cutaneous findings in genodermatoses is challenging, and first-line therapies, such as steroids and/or retinoids, are often inadequate. In recent years, research on the molecular basis of genodermatoses has led to the use of biologic therapies for intractable disease. Here, we review the evidence regarding the use of available biologic therapies for the management of dermatologic findings in genodermatoses. Biologic therapies appear to be promising therapeutic options for several recalcitrant genodermatoses, especially those with un...
Source: American Journal of Clinical Dermatology - May 23, 2022 Category: Dermatology Source Type: research

The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy
This article reviews recent advances in epidemiology, sarcoidosis clinical assessment with a focus on the dermatologist ’s role, disease pathogenesis, and new therapies in use and under investigation for cutaneous and systemic sarcoidosis. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 18, 2022 Category: Dermatology Source Type: research

Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study
ConclusionsRituximab use as adjuvant therapy within 12 weeks after initiation of systemic corticosteroids was associated with a faster and higher rate of achieving complete remission on minimal therapy or off therapy, as well as a significant corticosteroid-sparing effect and a comparable safety profile in this retrospective study. Hence, initial combination therapy with corticosteroids and adjuvant rituximab could serve as an effective treatment option for bullous pemphigoid, but this requires confirmation in randomized controlled studies. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 17, 2022 Category: Dermatology Source Type: research

Meat Allergy: A Ticking Time Bomb
AbstractFood allergies are relatively prevalent, but mammalian meat allergy remains uncommon and represents an important, potentially acute healthcare risk. This risk is partly because both clinicians and the public lack awareness of this serious allergy, which is unique in three important ways: it incurs a delayed reaction, it is induced by a carbohydrate rather than a protein, and it is linked to tick bites. Although various symptoms are possible, its unique presentation means that mammalian meat allergy is often presented to the dermatologist. We review this challenging subject, which is particularly salient considering...
Source: American Journal of Clinical Dermatology - May 16, 2022 Category: Dermatology Source Type: research

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
ConclusionsConsistent with results seen with short-term treatment, long-term treatment with dupilumab showed an acceptable safety profile while providing incremental clinical benefit with continued treatment over time. The high proportion of patients who needed uptitration because of inadequate response to q4w dosing supports the q2w dose regimen as optimal for this age group. Finally, the majority of patients who stopped medication after having clear/almost clear skin sustained over 12  weeks experienced disease recurrence, suggesting the need for continued dupilumab dosing to maintain efficacy.Trial RegistrationClinical...
Source: American Journal of Clinical Dermatology - May 14, 2022 Category: Dermatology Source Type: research

Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data
ConclusionsThis post-hoc analysis shows that patients who initiated treatment using chlormethine gel had faster and higher responses compared with patients who initially used chlormethine ointment for 12 months. The development of contact dermatitis may be a potential prognostic factor for response.Trial Registration Numbers and Dates of RegistrationStudy 201: NCT00168064, September 14, 2002; Study 202: NCT00535470, September 26, 2007. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 10, 2022 Category: Dermatology Source Type: research

Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents
AbstractBrain metastases from melanoma are no longer uniformly associated with dismal outcomes. Impressive tumor tissue-based (craniotomy) translational research has consistently shown that distinct patient subgroups may have a favorable prognosis. This review provides a historical overview of the standard-of-care treatments until the early 2010s. It subsequently summarizes more recent advances in understanding the biology of melanoma brain metastases (MBMs)  and treating patients with MBMs, mainly focusing upon prospective clinical trials of BRAF/MEK and PD-1/CTLA-4 inhibitors in patients with previously untreated MBMs. ...
Source: American Journal of Clinical Dermatology - May 9, 2022 Category: Dermatology Source Type: research

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
ConclusionThese results support dupilumab as continuous long-term treatment for adults with moderate-to-severe AD; efficacy was sustained following transition from qw to q2w dosing.Trial Registration ClinicalTrials.govNCT01949311. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 3, 2022 Category: Dermatology Source Type: research

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
AbstractBaricitinib (Olumiant®) is an oral small molecule inhibitor of Janus kinase (JAK)1 and JAK2, which have been implicated in the pathogenesis of atopic dermatitis (AD). In phase III studies in adults with moderate to severe AD who were inadequately controlled with topical corticosteroids (TCS) or systemic treatments (e.g. ciclosporin), or for whom these therapies were not advisable, baricitinib, alone or in combination with TCS, achieved significant and/or clinically relevant improvements in multiple measures of disease severity, pruritus, skin pain, sleep disturbance and health-related quality of life (HR-QOL) over...
Source: American Journal of Clinical Dermatology - May 3, 2022 Category: Dermatology Source Type: research